trending Market Intelligence /marketintelligence/en/news-insights/trending/Y8C2ab4g8M2mvjrDUNooYA2 content esgSubNav
In This List

Summit Therapeutics closes $25M placement of American depositary shares

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Summit Therapeutics closes $25M placement of American depositary shares

Summit Therapeutics PLC completed a private placement of 15,625,000 American depositary shares at $1.60 apiece to raise $25 million.

The ADS in the offering represented 78,125,000 new ordinary shares of Summit Therapeutics.

U.K.-based Summit Therapeutics said the new ordinary shares sold under the placement were listed on the London Stock Exchange's AIM market and started trading Jan. 9.

Summit Therapeutics is a biopharmaceutical company that focuses on the discovery, development and commercialization of novel medicines to treat rare and infectious diseases.